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ABSTRACT
Despite the recent progress in our understanding of clear cell renal cell carcinomas 
(ccRCCs), the etiology of ccRCC remains unclear. We reported here a prevailing 
reduction of the raf kinase inhibitory protein (RKIP) in ccRCC. In our examination 
of more than 600 ccRCC patients by western blot and immunohistochemistry, RKIP 
was significantly reduced in 80% of tumors. Inhibition of RKIP transcription in ccRCC  
occurs to greater levels than VHL transcription based on the quantification analysis of 
their transcripts in six large datasets of DNA microarray available in Oncomine™ with 
the median rank of suppression being 582 and 2343 for RKIP and VHL, respectively. 
Collectively, the magnitude of RKIP reduction and the levels of its downregulation 
match those of VHL. Furthermore, RKIP displays tumor suppressing activity in ccRCC. 
While modulation of RKIP expression did not affect the proliferation of A498 and 
786-0 ccRCC cells and neither their ability to form xenograft tumors in NOD/SCID 
mice, ectopic expression or knockdown of RKIP inhibited or enhanced A498 and 
786-0 ccRCC cell invasion, respectively. This was associated with robust changes 
in vimentin expression, a marker of EMT. Taken together, we demonstrate here 
that downregulation of RKIP occurs frequently at a rate that reaches that of VHL, 
suggesting RKIP being a critical tumor suppressor for ccRCC. This is consistent with 
RKIP being a tumor suppressor for other cancers.
INTRODUCTION
Renal cell carcinoma (RCC) accounts for 85% of 
kidney cancer cases. In 2008, 54,390 new cases of RCC 
were diagnosed in the United States and 13,010 (23.9%) 
of the patients died from the disease [1]. The main 
histological types of RCC are clear cell (ccRCC, 75%), 
papillary (pRCC, 12%), chromophobe (cRCC, 4%), 
and oncocytoma (4%) [2]. Clear cell RCC is the most 
prevalent, the most aggressive [3], and the most common 
cause of kidney cancer-associated deaths [4].
Loss of VHL is a critical event for ccRCC 
tumorigenesis. Patients with germline mutations of VHL 
are at risk of developing ccRCC with up to 600 tumors 
and 1100 cysts per kidney [5]; somatic mutations leading 
to biallellic inactivation of VHL occur in 50%–60% 
of sporadic ccRCCs [6]; VHL promoter methylation 
was observed in 15% of ccRCCs [7]. A recent report Oncotarget 7407 www.impactjournals.com/oncotarget
revealed an even higher rate (82.4%) of VHL somatic 
mutations and 8.3% of the VHL promoter CpG island 
hypermethylation [8]. Collectively accumulating evidence 
clearly demonstrates VHL being a critical tumor suppressor 
of  ccRCC.  However,  loss  of  VHL  is  not  sufficient. 
Patients with VHL deficiency develop ccRCCs that are 
often preceded by pre-neoplastic renal cysts [9] and mice 
deficient in VHL in the proximal tubule epithelium only 
develop low levels of renal cysts [10], demonstrating the 
requirement of other oncogenic events.
RKIP suppresses multiple oncogenic pathways 
[11,12]. The protein binds to the N-terminus of Raf-1, 
 preventing its interaction with MEK, an event that is 
required for MEK activation [13,14,11]; the association 
also impedes phosphorylation of Raf-1 at serine 338 
(S338) and tyrosine 341 (Y341) [15], mandatory events 
for Raf-1 activation [16,17]. Furthermore, growth factor 
signals which activate Raf-1/MEK/ERK pathway induce 
phosphorylation of RKIP at S153, resulting in RKIP being 
incapable of binding Raf-1 [18]. RKIP indirectly inhibits 
Wnt signaling by binding and stabilizing the glycogen 
synthase kinase 3-β (GSK3β) [19], and RKIP impedes 
NF-κB function by down-regulation of IκB kinase activity 
[20]. NF-κB plays a major role in up-regulation of Snail 
[21,22]. Snail is a major contributor of EMT, an essential 
process of cancer metastasis [23,24]. Consistent with these 
observations, the polycomb protein EZH2 was reported 
to promote the invasion of breast and prostate cancers 
via suppression of RKIP transcription [25], and RKIP 
has been demonstrated to inhibit metastasis of multiple 
human cancers, including prostate, breast, melanoma, and 
colorectal cancers, and gastrointestinal stromal tumors 
[26-32]. However, it remains unclear whether RKIP is also 
a tumor suppressor of ccRCC.
By  using  2D  gel-coupled  mass  spectrometry, 
western blot, and immunohistochemistry (IHC), we 
observed a common RKIP reduction in 80% of more 
than 600 cases of ccRCC examined. The levels of RKIP 
reduction follow ccRCC progression and metastasis. 
Furthermore, modulation of RKIP in ccRCC A498 and 
786-0 cells accordingly affected vimentin expression, 
a marker of EMT, along with affecting ccRCC cell 
invasion. Collectively, we provide evidence that RKIP can 
be an important tumor suppressor of ccRCC.
RESULTS
Common reduction of RKIP in ccRCC
We have collected RCC and the adjacent non-tumor 
kidney (ANK) tissue from 90 RCC patients. Tissue lysates 
were analyzed for actin by western blot and patients 
where actin was not readily detected in either tissue 
(data not shown) were excluded. The resulting patient 
cohort consisted of 50 ccRCC (Supplementary Table 1),   
13 pRCC, and other histological types of RCC (data 
not shown). We subsequently focused on ccRCC, as the 
number of cases for the other histological types was not 
sufficient for a valid statistical analysis.
To find unique proteins present in either ccRCC 
or  ANK  tissues,  we  performed  2D-gel  analysis  for 
several patients. One spot with a molecular weight 
of approximately 20 kDa and pI 7.42 was commonly 
detected in ANK, which was consistently reduced in the 
respective ccRCC (Fig. 1A). Mass spectrometry analysis 
of the spot recovered 97.3% of peptide sequences, which 
matched to the mammalian RKIP (data not shown). To 
confirm RKIP reduction, RKIP in ccRCC and ANK tissues 
was examined by western blot and IHC. In comparison 
to ANKs, dramatic reductions of RKIP in ccRCC were 
clearly detected (Fig. 1B, C). Additionally, RKIP was 
primarily expressed in the proximal tubules (Fig. 1C). As 
ccRCC is widely regarded to derive from the proximal 
tubular epithelial cells [9,33,34], the reduction of RKIP in 
ccRCC suggests RKIP being a candidate tumor suppressor 
of ccRCC. This concept is consistent with the reports that 
RKIP is a tumor suppressor for a variety of human cancers 
[11,12].
To quantify RKIP, we analyzed RKIP in 50 ccRCC 
and the respective ANK tissues. After normalization to 
actin, the RKIP protein levels in ccRCC were significantly 
lower than those in the ANK tissues (Fig. 1D). Except for 
(Continued)
Figure 1: Reduction of RKIP in ccRCC. (A) ccRCC and its adjacent non-tumor kidney tissue lysate was separated using 2-D gel 
(pH 3-10). Signals were developed by coomassie blue staining. The unique spot in the adjacent non-tumor kidney tissue was indicated. 
(B) Western blot analysis for RKIP in ccRCC and ANK for 50 ccRCC patients. Typical results for the indicated patients are shown. Oncotarget 7408 www.impactjournals.com/oncotarget
5 patients, the ratios of RKIP protein in ccRCC versus 
ANK (ccRCC/ANK) were below 1.0 in 90% (45/50) 
of ccRCC (Fig. 2A, Supplementary Table 1). Since the 
typical feature of ccRCC is the common reduction of 
VHL in up to 91% of ccRCC, we also examined the VHL 
protein. In 50 patients, 88% (44/50) of ccRCCs displayed 
reduced  VHL  in  comparison  to  ANKs  (Fig.  2B).  To 
further investigate RKIP downregulation in comparison 
to VHL reduction, we determined their expressions in 6 
datasets of DNA microarray (Oncomine™) [35-40]. RKIP 
transcription was suppressed to greater levels than that of 
VHL in all 6 datasets with the median rank of suppression 
being 582 and 2343 for RKIP and VHL, respectively (Table 
1). Taken together, reduction of RKIP in ccRCC reaches the 
magnitude and the level of VHL downregulation (Fig. 2).   
As 20 ccRCCs showed undetectable VHL (Fig. 2B, see 
the dots on the X-axis) versus 5 ccRCC with undetectable 
RKIP (Fig. 2A), the tumorigenesis of ccRCC most likely 
relies heavily on the loss of VHL function and on the 
partial reduction of RKIP action.
Reduction of RKIP generally correlates with 
ccRCC progression
To further investigate the relationship between 
RKIP reduction and ccRCC tumorigenesis, a set of tissue 
microarray  (TMA)  slides  (KD806,  KD951,  KD2085, 
KD2088  and  KD6161)  from  US  Biomax  were  used, 
which contained 45 cases of normal kidney tissues (NKT) 
and 571 ccRCCs (556 organ-confined tumors without 
Figure 1:  (C) Immunohisochemistry (IHC) staining for RKIP in ANK and ccRCC. The asterisks indicate kidney distal tubules. (D) Based 
on western blot analysis of RKIP in ANK and ccRCC tissues for 50 ccRCC patients (Supplementary Table 1), RKIP in ANK and ccRCC 
was normalized to the respective actin (Supplementary Table 1). Means ± SE (standard error) of the RKIP protein in ANK and ccRCC are 
graphed. * p ≤ 0.05 (2-tailed student t-test).Oncotarget 7409 www.impactjournals.com/oncotarget
Figure 2: The magnitude of reduction of RKIP and VHL in ccRCC. Levels of RKIP and VHL in ccRCC and the ANK tissues 
for 50 ccRCC patients were determined by western blot, followed by normalization to the respective actin. The ratios of RKIP (A) and VHL 
(B) in ccRCC versus ANK (ccRCC/ANK) were determined and plotted.
Table 1: The expression of RKIP and VHL mRNA in ccRCC.
mRNA Under-expression
Dataset Sample Set1 Genes2 Samples 
Examined




















12,624 20 416 2.90E-6 1415 0.075
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19,574 67 5339 0.137 13201 0.757
Yusenko 
et al., 2009
Median Rank 582 1.61E-6 2343 0.002
Oncomine™ (Compendia Bioscience, Ann Arbor, MI) was used to analyze mRNA microarray data from 6 available data 
sets. Comparisons are indicated in the Sample set column.
1Only ccRCC cases in the datasets were used;
2The number of genes analyzed.Oncotarget 7410 www.impactjournals.com/oncotarget
metastasis and 15 carcinomas with metastasis). Sixteen 
cases were excluded because of poor quality. Among 
45 NKTs, 93.3% showed readily detectable RKIP (Fig. 
3A); among 540 cases of ccRCC, 80.7% displayed 
dramatically reduced RKIP (Fig. 3A). The percentage of 
RKIP reduction in these ccRCC populations is consistent 
with that observed in our patient cohort.
We subsequently examined RKIP expression in the 
course of ccRCC progression. The organ-confined ccRCCs 
could be categorized according to either TNM (T: primary 
tumor size, N: lymph node metastasis, M: long distance 
metastasis) tumor stage (total 540 cases) or Fuhrman grade 
(total 486 cases) (Supplementary Table 2). To analyze 
RKIP expression, we divided the cases with H-Score 
≥ 260 to the strong expression group and the cases with 
H-Score < 260 to the weak expression group. This system 
has been widely used to analyze TMA [41,42,34]. In 
organ-confined ccRCCs, the number of carcinomas in 
the strong expression group was clearly decreased from 
T2N0M0 tumors to T3N0M0 carcinomas as well as from 
Fuhrman grade 1 tumors to Fuhrman grade 2 carcinomas 
(Fig. 3B, C). The levels of RKIP expression based on the 
H-Scores were also significantly decreased from NKT to 
ccRCC, from T2N0M0 to T3N0M0, and from Fuhrman 
grade 1 to Fuhrman grade 2 (Fig. 3D, E). While we could 
not establish a significant RKIP reduction from organ-
confined ccRCC without metastasis to local carcinomas 
with metastasis, which was likely attributable to our 
Figure 3: Reduction of RKIP correlates with ccRCC progression. (A) Typical images of RKIP staining for normal kidney and 
ccRCC tissues in a set of TMA containing 540 patients with organ-confined ccRCC. The percentage of tissues with strong (normal kidney 
tissue) or weak (ccRCCs) RKIP staining are indicated. (B and C) Numbers of tissues with strong (H-Score ≥ 260) versus weak staining 
(H-Score < 260) of RKIP are graphed based on the TNM stages and Fuhrman grade as indicated. The percentages of tissues with strong 
RKIP staining for normal kidney tissues (NKT) and individual tumor groups are indicated (top). (D and E) The average of RKIP expression 
(H-Scores) ± SE for normal kidney tissues and ccRCCs in individual TNM stages (D) and Fuhrman grades (E) are graphed. * p < 0.001 
between normal kidney tissues and the ccRCCs of individual TNM stages (D) or Fuhrman grades (E) (one-way ANOVA); # p < 0.05 
between T2N0M0 and T3N0M0/T4N0M0 (D); # p < 0.001 between Fuhrman grades 1 and 2/3 (E) (one-way ANOVA). 
(Continued)Oncotarget 7411 www.impactjournals.com/oncotarget
limited cases of the latter group, a trend of RKIP reduction 
was observed (Fig. 3F). Within the 15 cases of local 
carcinoma with metastasis, tissues from the metastasized 
organ (adrenal gland, bone, lymph node, lung, thyroid, 
intestine, and spleen) were available for 8 cases; the RKIP 
levels were significantly lower in metastasized ccRCC 
compared to the local counterparts (Fig. 3F, G).
To further examine RKIP expression in metastasized 
ccRCC, we obtained 7 clinically confirmed metastasized 
ccRCCs from hospitals in Hamilton, including one tissue 
each from lymph node, back subcutaneous, colon, and lung 
chest wall, and three lung metastases (data not shown). 
At comparable staining conditions, RKIP expression was 
dramatically reduced in metastasized ccRCC compared 
to the non-tumor kidney tissues (data not shown). Taken 
together, in the total of 15 cases of metastasized ccRCC 
obtained from different patient cohorts RKIP expression 
was drastically reduced compared to NTK tissues.
We also determined whether RKIP levels associate 
with patient survival. In the patient population included in 
the TMAs (Supplementary Table 2), there were 25 patients 
with follow-up information. We noticed that organ-
confined ccRCCs without metastasis, with metastasis, and 
metastasized ccRCC have an average H-Score of RKIP at 
220, 204, and 181, respectively (Fig. 3F). These patients 
were thus analyzed based on H-Score > 204 or ≤ 204. 
Among 13 patients with RKIP > 204, 23% (3/13) died 
of ccRCC; in 12 patients with RKIP ≤ 204, 50% (6/12) 
died of cancer. To increase patient numbers, a new TMA 
was analyzed, which contained 14 RKIP-positive and 32 
RKIP-negative ccRCC (Supplementary Table 3); 3/14 
(21.4%) RKIP-positive and 12/32 (37.5%) RKIP-negative 
ccRCC patients died from the disease (Supplementary 
Table 3). Kaplan-Meier survival analysis indicated that 
patients with RKIP-negative ccRCC were likely to have 
poorer survival than those with RKIP-positive ccRCC 
(Fig. 3H). Similar results were also obtained when the 
RKIP transcription data in Oncomine™ were analyzed 
[43] (data not shown). However, in all these analyses, the 
differences were not statistically significant (Fig. 3H; data 
not shown). This is likely due to the limited number of 
patients available with followed-up information and the 
lack of sufficient number of patients with RKIP-positive 
ccRCC, as a result of a common RKIP reduction, adds an 
additional challenge.
Transcription regulation contributes to RKIP 
reduction in ccRCC
To investigate the mechanisms responsible for the 
observed RKIP reduction, we examined the levels of 
RKIP mRNA using real time PCR. While ANK tissues 
Figure 3: (F) RKIP expression in normal kidney tissue (NKT), primary ccRCC without (-) or with (+) metastasis, and metastasized 
ccRCC (means ± SE). * p < 0.001 between NKT and ccRCCs (one-way ANOVA); # p < 0.05 between primary ccRCC with metastasis 
and metastasized ccRCC (one-way ANOVA). The average H-Scores for individual groups of ccRCC are indicated. (G) Representative 
images of RKIP staining for the matched primary and metastasized ccRCC for 8 patients. (H) Kaplan-Meier surviving analysis for patients 
with ccRCC expressing RKIP at H-Score ≤ 204 (RKIP-, 30 patients) or > 204 (RKIP+, 13 patients). p = 0.1141 by Mantel-Cox Test and   
p = 0.1052 by Gehan-Breslow-Wilcoxon Test.Oncotarget 7412 www.impactjournals.com/oncotarget
consist of multiple cell types derived from glomeruli 
and distal tubules, RKIP is predominantly expressed in 
the proximal tubule epithelial cells (Fig. 1C). As there is 
no bona fide markers available specific for the proximal 
tubular epithelial cells, in which ccRCC is originated, it is 
impossible to compare the abundance of RKIP mRNA in 
the proximal tubular epithelial cells with that in ccRCC. 
However, we noticed that the RKIP protein levels in 
ccRCC vary significantly (Supplementary Table 1). Based 
on the ratios of RKIP protein (ccRCC/ANK), we first 
grouped ccRCCs into two levels, low (≤ 0.1) and high 
(≥0.8)  (Supplementary  Table  1).  After  normalization 
to actin, semi-quantitative real time PCR (qRT-PCR) 
demonstrated that RKIP mRNA levels followed the same 
order in the two groups (Fig. 4A). The ccRCC tumors 
were confirmed by the elevation of VEGF-A compared to 
ANK (data not shown). Collectively, these results support 
the notion that inhibition of RKIP transcription plays a 
role in its reduction in ccRCC.
To consolidate this concept, we demonstrated 
decreases in the RKIP protein in A498 and 786-0 ccRCC 
lines in comparison to human kidney proximal tubular 
epithelial HK2 cells (Supplementary Fig. 1). Promoter 
methylation has been shown to repress RKIP transcription 
[44]. To examine whether methylation is involved in 
RKIP reduction, A498 and 786-0 cells were treated with 
5-aza-2’-deoxycytidine (5-aza-dC, a widely used DNA 
methyltransferase inhibitor) at 2 µM for 48 hours. 5-aza-
dC increased RKIP at both mRNA and protein levels 
only in A498 cells (Fig. 4B, C). This is consistent with 
Figure 4: Regulation of RKIP transcription contributes to decease of RKIP in ccRCC. (A) Real-time PCR analysis of the 
RKIP transcripts in ccRCCs that express low or high levels of RKIP protein (see Supplementary Table 1 for details). Experiments were 
repeated three times. The relative abundance of RKIP mRNA was in reference to actin and means ± SD (standard derivation) are graphed. 
* p < 0.05 in comparison to the low group (2-tailed student t-test). (B and C) 786-0 and A498 cells were either mock-treated or treated 
with 5-aza-dC (2 µM) for 48 hours, followed by examination of the RKIP protein by western blot (B) and the RKIP transcript by real time 
PCR (C). Experiments were repeated in triplicate and means ± SE are graphed. * p < 0.05 in comparison to the mock-treatment (2-tailed 
student t-test).Oncotarget 7413 www.impactjournals.com/oncotarget
the observation that in comparison to HK2 cells RKIP is 
significantly reduced in A498 cells (Supplementary Fig. 1). 
Collectively, the above results reveal that transcriptional 
regulation contributes in part to the decrease of RKIP in 
ccRCC.
RKIP does not affect ccRCC proliferation and 
the formation of xenograft tumors
The most well characterized function of RKIP 
is the inhibition of Raf-1-mediated ERK activation. 
To determine the relationship between RKIP and ERK 
activation, western blot analysis was performed on 50 
cases of ccRCC; significant changes in ERK protein and 
in ERK activation between ccRCC and ANK could not be 
demonstrated (data not shown). This is consistent with the 
ERK activation levels being not reversely correlated with 
the RKIP protein abundance in A498, 786-0, and HK2 
cells (Supplementary Fig. 1).
We subsequently examined the impact of RKIP on 
ccRCC cell proliferation. Ectopic expression of FLAG-
tagged RKIP in A498 and 786-0 cells did not affect 
their proliferation (Fig. 5A, Supplementary Fig. 2A). 
Knockdown of endogenous RKIP in either line was 
also without effects (Fig. 5B, Supplementary Fig. 2B). 
Consistent with ERK activity promoting cell proliferation, 
these results are in line with the observations that RKIP 
expression did not reversely correlate with ERK activation 
in primary ccRCC (data not shown), A498 and 786-0 cells 
(Supplementary Fig. 1).
We further determined whether RKIP inhibits 
ccRCC tumorigenesis. A498 EV (empty vector), A498 
RKIP, A498 Ctrl shRNA, or A498 RKIP shRNA cells 
were  subcutaneously  implanted  into  NOD/SCID  mice 
(5 mice/cell line). Tumor incidence for all lines was 5 
for 5. The kinetics of xenograft tumor formation did not 
differ between EV and RKIP cells as well as between 
Ctrl shRNA and RKIP shRNA cells (Fig. 5C, D). Stable 
Figure 5: Modulation of RKIP does not affect A498 cell proliferation and neither the cell’s ability to form xenograft 
tumors in NOD/SCID mice. (A and B) A498 cell lines were constructed to express an empty vector (EV), FLAG-tagged RKIP, control 
(Ctrl) shRNA or RKIP shRNA. Ectopic expression and knockdown of RKIP were confirmed (insets). Cell’s proliferation ability was then 
determined. (C and D) A498 EV, RKIP, Ctrl shRNA, and RKIP shRNA cells (3x106) were implanted into NOD/SCID mice (5 mice per cell 
line). Tumor volumes were measured weekly. Xenograft tumors were formed in all five mice. Mean volumes ± SE were plotted.Oncotarget 7414 www.impactjournals.com/oncotarget
modulations of RKIP expression were demonstrated in 
A498 cells (Fig. 5A, B, see the insets) and in xenograft 
tumors (Supplementary Fig. 3). Collectively, we conclude 
that RKIP does not play a major role in inhibiting ERK 
activation, cell proliferation, and the formation of 
xenograft tumors in ccRCC cells. These observations are 
consistent with the reports that overexpression of RKIP 
did not affect the proliferation of breast and prostate 
cancer cells in vitro and their ability to form xenograft 
tumors in vivo [26,41].
RKIP reduces ccRCC cell invasion
RKIP has been shown to inhibit breast and prostate 
cancer metastasis [26,41]. Since the invasion ability of 
a cell is closely related to cancer’s metastatic potential, 
we have determined the impact of RKIP on ccRCC cell 
invasion. Overexpression of RKIP in A498 and 786-0 cell 
lines reduced their invasion ability in comparison to the 
EV cells (Fig. 6A, Supplementary Fig. 4A). Conversely, 
knockdown of RKIP in both lines robustly enhanced their 
invasion capacity (Fig. 6B, Supplementary Fig. 4B).
EMT is an essential process of metastasis [23,24]; 
RKIP inhibits EMT in breast and prostate cancers [26,41]. 
We thus examined the potential impact of RKIP on EMT 
in ccRCC cells. As most (95%) of primary ccRCCs 
do not express E-cadherin [42] and neither A498 and   
786-0 cells (data not shown), we determined the impact 
of RKIP on N-cadherin and vimentin, two-well recognized 
EMT markers. Ectopic expression and knockdown of 
RKIP modestly but significantly inhibited and enhanced 
N-cadherin expression in A498 cells, respectively (data 
not shown). Meanwhile, overexpression and knockdown 
of  RKIP  significantly  downregulated  and  upregulated 
Vimentin expression in A498 cells, respectively   
(Fig. 6C, D). Collectively, these observations support the 
notion that RKIP reduces ccRCC invasion at least in part 
via inhibiting EMT.
Figure 6: Modulations of RKIP affect A498 ccRCC cell invasion. (A and B) The indicated A498 cell lines were assayed for 
their invasion ability using either a control membrane or 8 µM matrigel membranes. Typical image of cells that have passed through either 
membrane are shown (left panels). Quantification of three independent repeats (means ± SE) is also graphed (right panels). * p < 0.01 in 
comparison to the respective controls (2-tailed student t-test). 
(Continued)Oncotarget 7415 www.impactjournals.com/oncotarget
DISCUSSION
Clear cell renal cell carcinoma is commonly 
associated with upregulation/activation of VEGF (vascular 
endothelial  growth  factor),  PDGF-β  (platelet-derived 
growth factor), and TGF-α [45,46]. These growth factors 
activate  a  major  oncogenic  event  -  the  Raf  pathway. 
Consistent with the pathway playing an important role in 
ccRCC evolution, we provide evidence that reduction of 
RKIP might facilitate ccRCC tumorigenesis.
Our observed reduction of RKIP in 80% of more 
than 600 ccRCC cases examined strongly suggests RKIP 
being a candidate gatekeeper for ccRCC. As VHL is 
reduced or lost in 75% of ccRCC cases, it can be predicted 
that at least 60% of ccRCCs will have both proteins 
reduced. This is in accordance with our observations in 
which 78% (39/50) of ccRCC have both incidences (data 
not shown). It will be interesting to examine how these two 
events together may impact ccRCC tumorigenesis. RKIP 
may not only be a gatekeeper for ccRCC, as reduction of 
RKIP has been observed in 50% of prostate cancers [47]. 
Regardless whether RKIP functions as a gatekeeper for 
ccRCC, prostate cancer, and other human cancers, it seems 
that reduction of RKIP needs other oncogenic signals for 
malignancy. This is because RKIP deficient mice do not 
develop tumors [48].
While  RKIP  is  dominantly  reduced  in  majority 
of ccRCC, modulations of RKIP expression did not 
affect A498 cell’s ability to produce xenograft tumors 
in NOD/SCID mice. Because A498 cells are cancerous 
cells, in which many changes have occurred, the above 
observations  may  not  truly  reflect  RKIP’s  ability  in 
suppressing  the  formation  of  primary  ccRCC.  Better 
animal models i.e. knockout and transgenic mice will 
be needed to conclusively address this issue. However, 
the observation that modulations of RKIP accordingly 
affected the invasion of A498 and 786-0 cells suggests 
that RKIP inhibits ccRCC metastasis. Similar observations 
were reported in prostate cancer, in which RKIP reduction 
affected the cell’s metastatic but not xenograft tumor 
forming ability [26,47]. This is in line with RKIP being an 
independent prognostic marker for patients with Dukes’ B 
colorectal cancer [49].
Although RKIP was best studied for its inhibition of 
Raf-initiated activation of MEK [50], an upstream kinase 
of ERK, it does not appear that RKIP suppresses ccRCC 
tumorigenesis mainly via inhibiting the Raf-MEK-ERK 
pathway (Supplementary Fig. 1, data not shown). This is 
consist with our observation that phosphorylation on S153 
of RKIP was not changed in ccRCC compared to that in 
the ANK tissues (data not shown) and this phosphorylation 
inactivates RKIP’s ability to prevent Raf from activating 
MEK [18]. On the other hand, evidence supports that 
RKIP inhibits ccRCC tumorigenesis and/or metastasis via 
inhibiting EMT, based the observations that modulations 
of RKIP accordingly affected A498 invasion along 
with changes in vimentin expression (Fig. 6). However, 
it remains unclear whether RKIP reduces vimentin 
expression at mRNA or protein levels. While 5-aza-
dC treatment elevated RKIP expression in A498 cells   
(Fig.  4B,  C),  the  treatment  did  not  increase  vimentin 
mRNA abundance (data not shown).
Although whether RKIP primarily inhibits ccRCC 
tumorigenesis and/or metastasis and the underlying 
mechanisms need further investigations, our observations 
that the RKIP protein is surprisingly reduced in 80% 
Figure 6: (C and D) A498 EV, RKIP, Ctrl shRNA, and shRKIP cells were examined for the expression of vimentin and actin by western 
blot (see the insets for typical results). Vimentin in individual cell lines were normalized to the respective actin. Experiments were repeated 
in triplicate. Means ± SE are graphed. * p < 0.05 in comparison to either A498 EV or Ctrl shRNA cells (2-tailed student t-test).Oncotarget 7416 www.impactjournals.com/oncotarget
of ccRCC strongly suggests a critical role of RKIP 
in preventing ccRCC tumorigenesis. Our research is 
consistent with a recent report showing decreases of RKIP 
in 42.2% of RCC and the association of RKIP reduction 
with RCC progression [51]. What are the mechanisms 




Kidney cancer and the adjacent non-tumor (ANK) 
tissues were collected at St. Joseph’s Hospital in Hamilton, 
Ontario, Canada with consent from patients and approval 
of the Research Ethics Board.
Modulation of gene expression in ccRCC cells
Stable expression of RKIP in A498 and 786-0   
ccRCC cells was achieved using retrovirus as we have 
previously described [52]. Knockdown of RKIP in 
A498 and 786-0 cells was carried out using a pRIH 
retroviral-based shRNA vector according to our published 
conditions [52]. The RKIP targeting sequence was 5’– 
GTGGGATGGTCTTGATTCA –3’. Both A498 and 786-0 
ccRCC lines are VHL deficient [53]
Cell proliferation and invasion assay
Cells were seeded at a density of 104 per well in 
6-well plates and cell numbers were determined daily for 
seven days. Triplicate wells were counted each day.
Invasion assays were performed using an 8 µm pore 
size matrigel membrane as previously described [54]. 
Briefly, insert chambers were placed into a 24-well plate 
(BD Biosciences). Serum containing medium was placed 
in the bottom chamber and cells suspended in serum-free 
medium were added to the top chamber. Cells that passed 
through control or matrigel membranes were stained with 
crystal violet. Percentage of invasive cells was calculated 
by dividing the number of cells passing through the 8 µm 
pore size matrigel membrane by the number of cells 
migrating through the control membrane and multiplying 
by 100.
Western blot analysis, immunohistochemistry 
(IHC), and real time PCR
Cell lysates were prepared and western blot was 
performed using anti-RKIP (1:500, Santa Cruz), anti-ERK 
(1:1000, Cell Signaling), anti-phosphoERK (1:1000, Cell 
Signaling), anti-FLAG (1:1000, Sigma), anti-N-Cadherin 
(1:1000, Sigma), anti-Vimentin (1:500, Santa Cruz), and 
anti-actin (1:1000, Santa Cruz).
IHC was executed using a set of tissue microarray 
(TMA) slides (KD806, KD951, KD2085, KD2088, and 
KD6161) from US Biomax (Rockville, MD) and IMH-
313 from Imgenex (San Diego, CA). Primary anti-RKIP 
antibody (1:500, Santa Cruz) was incubated with the 
sections overnight at 4°C. Biotinylated secondary IgG 
and  Vector  ABC  reagent  (Vector  Laboratories)  were 
subsequently added according to the manufacturer’s 
instructions. TMA slides were scanned using ScanScope 
and analyzed using ImageScope software (Aperio); scores 
obtained were converted to H-Score using the formula: 
H-Score = (% weak x 1 + % medium x 2 + % strong x   
3  +1)  x  100  [55,56,52].  H-Scores  ≥  260  and  <  260 
were considered strong and weak staining, respectively 
[55,56,52]. Each cancerous tissue core was in duplicate. 
All spots (stained cores) were also manually examined. 
Tissue cores were excluded from analysis if the tissue was 
scratched or missing majority of the sample.
Total RNA was isolated using TRIZOL (Invitrogen). 
Reverse transcription was carried out using superscript 
III (Invitrogen) according to manufacturer’s instruction. 
Real time PCR primers used for RKIP, VEGF, and actin 
are listed in Supplementary Table 4. Real-time PCR was 
performed  using  the  ABI  7500  Fast  Real-Time  PCR 
System (Applied Biosystems) in the presence of SYBR-
green according to the manufacturer’s instructions 
(Applied Biosystems). Gene expression was measured 
relative to actin expression using the following formula 
for the relative transcript abundance (RTA): RTA = 
10,000/2(CTgene-CTactin) [57].
Generation of xenograft tumors
A498 cells (3x106) overexpressing an empty vector 
(EV), RKIP (RKIP), short hairpin control (Ctrl ShRNA) 
or RKIP ShRNA were resuspended into a MEM/Matrigel 
mixture (1:1 volume) and subcutaneously implanted into 
the flank of NOD/SCID mice (The Jackson Laboratory) 
with each group containing 5 mice. Tumor volume was 
calculated according to the formula L x W2 x 0.52, where L 
and W are the longest and shortest diameters respectively 
[58]. All animal work was performed according to 
protocols approved by the McMaster University Animal 
Research Ethics.
Statistical analysis
All data are presented as mean ± standard error (SE). 
Statistical analysis was carried out using the statistical 
program SPSS Statistics 17.0 for Windows. Two-tailed 
Student’s T-Test was used. Pearson’s correlation was used 
to test relationships between RKIP protein expression and 
tumor stage and tumor grade progression. One way analysis 
of variance (ANOVA) was performed to evaluate effect 
of tumor stage, tumor grade and metastasis on H-Score.   
A p-value <0.05 was considered statistically significant.Oncotarget 7417 www.impactjournals.com/oncotarget
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